Entheses are predominantly extra-articularly localized structures that represent a key target of musculoskeletal inflammation in diseases such as psoriatic arthritis (PsA) and spondyloarthritis (SpA) ...

Ultrasound assessment of enthesitis can effectively distinguish patients with vs without SpA, with inflammatory B-mode lesions serving as the strongest independent marker.

Enthesitis, inflammation of the entheses (sites where tendons and ligaments attach to the bone), is a common feature of inflammatory arthritis. It is most prevalent in patients with psoriatic ...

Please provide your email address to receive an email when new articles are posted on . Children with enthesitis demonstrate worse patient-reported outcomes compared with those without, regardless of ...

Patients with hidradenitis suppurativa (HS) may have subclinical spondyloarthritis (SpA) features, e.g., sacroiliitis and ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving tofacitinib had fewer enthesitis relapses following initial resolution after 1 or 3 months.

Patients with ankylosing spondylitis taking secukinumab saw improvements in enthesitis, and some achieved complete resolution, suggesting the drug could be a viable option for patients intolerant of ...

In this cross-sectional study, Poggenborg and colleagues evaluated the ability of an emerging imaging technology, "whole-body" MRI (WBMRI), to detect enthesitis in patients with psoriatic arthritis ...

Patients with psoriatic arthritis with enthesitis are more likely to have severe disease than patients without enthesitis, and they and their physicians are less likely to be satisfied with their ...

The severity of enthesitis in psoriatic arthritis is a potential marker for severe disease and joint damage, a cross-sectional study found. For instance, a 10-unit increase on the Madrid Sonographic ...

The monoclonal antibody guselkumab (Tremfya), which targets the p19 subunit of interleukin (IL)-23, was effective for treating the enthesitis and dactylitis components of psoriatic arthritis (PsA), ...

The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA. The Food and Drug ...